|Mr. Charles Daniel Myers||Co-Founder, Chief Exec. Officer and Director||654.39k||N/A||63|
|Mr. Richard S. Eiswirth Jr.||Pres and Chief Financial Officer||517.85k||N/A||49|
|Dr. Kenneth Green Ph.D.||Chief Scientific Officer, Global Head of R&D and Sr. VP||454.01k||N/A||59|
|Mr. David R. Holland||Co-Founder and Sr. VP of Sales & Marketing||N/A||N/A||53|
|Mr. Jeffrey W. Burris||VP, Gen. Counsel and Sec.||N/A||N/A||45|
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patients eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans other than uveitis or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Alimera Sciences, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 8; Compensation: 10.